The compounded vs branded GLP-1 question changed in 2025. Compounded semaglutide and tirzepatide were widely available during the FDA-declared shortage from 2021 to 2025, and using them was legal and common. The shortage has since resolved, and large-scale compounding of these drugs is now restricted. The standard of care is branded, FDA-approved medication: Wegovy or Zepbound for weight management.
If you used compounded GLP-1, you did nothing wrong. The regulatory ground shifted under everyone. This guide explains what changed and what the safer path looks like now.
- Compounded semaglutide/tirzepatide were legal during the 2021–2025 FDA shortage; that shortage has now resolved.
- Large-scale compounding is now restricted, and branded, FDA-approved Wegovy or Zepbound is the standard of care.
- Branded drugs carry verified dose, potency, and purity; compounded products vary between pharmacies and batches.
- Cost, the real reason people compounded, can be lowered legitimately through prior authorization and manufacturer savings programs.
- If currently on compounded GLP-1, the transition to branded medication should be planned with a clinician, not abrupt.
- GoodLife's medical weight loss sits in the $399/month membership tier, with no markup on the medication itself.
What compounded GLP-1 was
Compounded medications are mixed by a pharmacy rather than manufactured by the brand maker. During a declared drug shortage, federal rules allow compounding pharmacies to prepare versions of a drug that is in short supply, which is exactly what happened with semaglutide and tirzepatide as demand outran supply. For several years, compounded GLP-1 was a legal, lower-cost way to access the medication when the branded product was hard to get.
That access was real, and patients who used it were responding rationally to a shortage. The issue was never the patient. It was that compounded products are not FDA-reviewed for safety, potency, and consistency the way the branded drugs are, and that distinction became decisive once the shortage ended.
What changed in 2025
The FDA removed semaglutide and tirzepatide from the shortage list, and the legal basis for routine, large-scale compounding went with it. With the branded supply restored, the conditions that allowed widespread compounding no longer apply, and the standard of care is the FDA-approved branded medication.
This is a regulatory change, not a verdict on anyone who used compounded drug during the shortage. The right framing is simple: the ground shifted, here is what changed, and here is the safer path now.
If you used compounded GLP-1, you did nothing wrong. The regulatory ground shifted under everyone.
Why branded is the standard now
Branded Wegovy (semaglutide) and Zepbound (tirzepatide) are manufactured under FDA oversight, with verified dosing, potency, and purity. That consistency matters most during titration, when small differences in dose drive both results and side effects. Compounded products vary between pharmacies and batches, which introduces uncertainty exactly where precision matters. With branded supply restored, there is no shortage rationale to accept that uncertainty.
Compounded vs. Branded GLP-1
Why the distinction now matters
| Factor | Compounded GLP-1 | Branded GLP-1 (Wegovy/Zepbound) |
|---|---|---|
| Manufacturing oversight | Mixed by pharmacy, not FDA-reviewed | Manufactured under FDA oversight |
| Dose/potency consistency | Varies between pharmacies and batches | Verified dosing, potency, and purity |
| Legal basis | Allowed during declared shortage (2021–2025) | Now the standard of care post-shortage |
| Cost profile | Lower-cost during shortage era | Higher list price, offset via PA and savings programs |
That consistency matters most during titration, when small differences in dose drive both results and side effects. Compounded products vary between pharmacies and batches, which introduces uncertainty exactly where precision matters.
For how the two branded options compare, see our guide on Wegovy versus Zepbound, and for the broader landscape, the best GLP-1 medications for weight loss.
The safer path to affordable branded medication
Cost is the real reason people turned to compounding, and there are legitimate ways to lower the cost of branded medication:
- Pursue prior authorization through your insurance with your clinician's documentation.
- Use manufacturer savings programs, which can substantially cut the monthly price for eligible patients.
- Match the medication to coverage, since plans differ on which GLP-1 they cover and for which indication.
The answer to a high price is to work the access channels, not to substitute a compounded product to save money now that the shortage has ended. At GoodLife Health, a clinician handles the prior authorization and documentation as part of the care, and you pay the pharmacy directly for the medication with no markup from GoodLife.
How GoodLife handles it
GoodLife is a direct primary care telehealth membership, not a pharmacy or a compounder, and it does not sell or take title to medication. Medical weight loss sits in the 399 dollar a month tier. The membership pays for the clinician, who prescribes branded FDA-approved medication when appropriate, pursues coverage and savings, and supervises titration. The drug is a separate pharmacy cost. That separation is the point: GoodLife earns nothing on the prescription, so the advice about which medication to use is not a sales pitch.
What to do if you are currently on compounded GLP-1
If you are taking compounded semaglutide or tirzepatide right now, the first thing to know is that you do not need to panic, and you should not simply stop on your own. Stopping abruptly without a plan tends to bring back appetite and regain weight, which undoes the progress you made. The goal is an orderly transition, not a cliff.
Start by talking with a clinician about moving to branded, FDA-approved medication. In most cases the transition is straightforward: you match your current dose to the nearest appropriate branded dose and continue, often without restarting titration from the bottom if you are already tolerating a steady dose. Your clinician will confirm the right step based on where you are.
Then work the cost problem the right way. The reason most people chose compounding was price, and that problem is solvable through legitimate channels: prior authorization with your clinician's documentation, manufacturer savings programs, and matching the medication to what your plan actually covers. These can bring the branded cost down substantially, and they do not carry the consistency and oversight concerns of compounded product now that the shortage has ended.
Keep the supervision in place through the switch. This is a good moment to confirm your labs, review side effects, and make sure the plan still includes the protein and resistance-training pieces that protect muscle. A transition is a natural checkpoint for the whole program, not just the prescription.
Finally, drop any sense that the earlier choice was a failure. Using compounded GLP-1 during the shortage was legal and rational. The regulatory ground shifted, and adjusting to it is simply good medicine. The framing that matters is forward-looking: here is what changed, here is the safer path, and here is how to keep the results you have already earned. Handled this way, the switch is a routine step, not a setback, and it protects both your progress and your safety.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Routine large-scale compounding of semaglutide is now restricted because the FDA shortage that permitted it has resolved. The standard of care is branded, FDA-approved medication. Narrow, individualized compounding can still occur in specific clinical situations, but it is no longer a broad, low-cost access route.
Did I do something wrong by using compounded GLP-1?
No. Compounded GLP-1 was legal and widely used during the 2021 to 2025 shortage. The regulatory situation changed when the shortage ended. The reasonable next step is to move to branded medication, not to feel that the earlier choice was a mistake.
Why is branded GLP-1 considered safer than compounded?
Branded Wegovy and Zepbound are made under FDA oversight with verified dose, potency, and purity. Compounded products vary between pharmacies and batches, which adds uncertainty during titration, when precise dosing matters most.
How can I afford branded GLP-1 medication?
Work the access channels: prior authorization with your clinician's documentation, manufacturer savings programs, and matching the medication to what your plan covers. These can substantially lower the monthly cost without relying on compounding.
Does GoodLife sell compounded GLP-1?
No. GoodLife is a direct primary care telehealth membership, not a pharmacy or compounder. It does not sell or take title to medication. A clinician prescribes branded FDA-approved medication when appropriate, and you pay the pharmacy directly.
Related Reading
- GLP-1 Prior Authorization for Weight Loss Medication: A Step-by-Step Guide
- GLP-1 Side Effects: What to Expect and How to Manage Them
- GLP-1 Weight Loss Plateau: Why It Happens and How to Break It
- Ozempic vs Wegovy: Same Drug, Different Approval, What It Means
- Best Medical Weight Loss Programs: The Clinically Honest Guide for 2026
References
- U.S. Food and Drug Administration. Medications Containing Semaglutide: Safety Information and Compounding.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022.
This article is informational only and is not medical advice. GoodLife Health is a direct primary care telehealth membership, not a pharmacy, compounder, or supplement seller, and does not sell or dispense medication. Individual results vary. Consult a licensed clinician.